MedTrace Logo

Apatinib in Combination With Stereotactic Body Radiation Therapy (SBRT) Treatment for Symptomatic Metastatic Prostate Cancer

NCT02998242 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2019-05-21

No results posted yet for this study

Summary

To study safety and efficacy of apatinib in combination of radiotherapy in patients with symptomatic bony disease prostate cancer (SBPC), based on the potential synergistic antitumor activity between Apatinib and Stereotactic Body Radiation Therapy (SBRT).

Conditions

  • Quality of Life

Interventions

DRUG

Apatinib

RADIATION

SBRT to symptomatic bony metastatic bony site(s)

Sponsors & Collaborators

  • Chang'An Hospital

    collaborator OTHER

  • Hainan Medical College

    collaborator OTHER

  • Sichuan Provincial People's Hospital

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-10
Primary Completion
2017-01-05
Completion
2017-12-10

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02998242 on ClinicalTrials.gov